World Journal of Urology

• 

  Publication Venue For

  • Contemporary analysis of management of isolated pendulous urethral strictures using pedicled skin flap urethroplasty repair. 2019
  • Surveillance after prostate focal therapy..  37:397-407. 2019
  • Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project 2019
  • Molecular markers in bladder cancer..  37:31-40. 2019
  • Donor kidney volume measured by computed tomography is a strong predictor of recipient eGFR in living donor kidney transplantation 2018
  • Antibiotic use and the prevention and management of infectious complications in stone disease..  35:1369-1379. 2017
  • The economics of stone disease..  35:1321-1329. 2017
  • Cost-effectiveness comparison of ureteral calculi treated with ureteroscopic laser lithotripsy versus shockwave lithotripsy..  35:161-166. 2017
  • Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project..  33:1503-1509. 2015
  • Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence?.  33:1309-1313. 2015
  • Resident involvement and experience do not affect perioperative complications following robotic prostatectomy..  33:793-799. 2015
  • Disposable devices for RIRS: where do we stand in 2013? What do we need in the future?.  33:241-246. 2015
  • Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy..  33:93-97. 2015
  • The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy..  32:323-328. 2014
  • Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group..  32:185-191. 2014
  • Lichen sclerosus in men is associated with elevated body mass index, diabetes mellitus, coronary artery disease and smoking..  32:105-108. 2014
  • Disposable devices for RIRS: Where do we stand in 2013? What do we need in the future?.  33:241-246. 2014
  • The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy.  32:323-328. 2014
  • Intratumoral inflammation is associated with more aggressive prostate cancer..  31:1497-1503. 2013
  • Nephrostomy in percutaneous nephrolithotomy (PCNL): does nephrostomy tube size matter? Results from the Global PCNL Study from the Clinical Research Office Endourology Society..  31:1563-1568. 2013
  • The use of mannitol in partial and live donor nephrectomy: an international survey..  31:977-982. 2013
  • The use of mannitol in partial and live donor nephrectomy: An international survey.  31:977-982. 2013
  • Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group..  30:181-187. 2012
  • Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group..  30:149-155. 2012
  • Nephrostomy in percutaneous nephrolithotomy (PCNL): does nephrostomy tube size matter? Results from The Global PCNL Study from The Clinical Research Office Endourology Society.  1-6. 2012
  • Education and training in evidence-based urology..  29:325-329. 2011
  • Impact of marital status in patients undergoing radical cystectomy for bladder cancer..  27:573-576. 2009
  • Holmium laser for stone management..  25:235-239. 2007
  • Fascicular anatomy and surgical access of the human pudendal nerve..  23:411-418. 2005
  • Contemporary chemotherapeutic approaches for the treatment of hormone-refractory prostate carcinoma..  18:216-221. 2000
  • Outcome profiles of locoregional disease after radical prostatectomy and radiotherapy..  18:173-178. 2000
  • Gene therapy in urologic oncology..  18:91-92. 2000
  • Dorsal onlay urethroplasty for urethral stricture repair..  16:181-185. 1998
  • Peptidyl membrane-interactive molecules are cytotoxic to prostatic cancer cells in vitro..  16:405-409. 1998
  • Molecular determinants of sexual differentiation..  14:278-294. 1996
  • Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival?.  12:308-312. 1994
  • The impact of the "cisplatin era" of treatment on survival in testicular cancer.  9:45-50. 1991
  • Augmentation cystoplasty.  8:203-207. 1990
  • Refusal of cancer therapy in testicular cancer: Recognizing and preventing a significant problem.  8:58-62. 1990
  • The evolving role for surgery in the management of nonseminomatous testicular carcinoma.  8:13-19. 1990
  • Editorial.  7:1. 1989
  • Stage A prostatic adenocarcinoma - An artifact of detection.  7:34-37. 1989
  • The role of radical prostatectomy in the management of prostatic adenocarcinoma - Biologic factors influencing the likelihood of local and systemic control.  7:38-44. 1989
  • Repair of the difficult posterior urethral stricture.  5:30-36. 1987
  • A review: prostate monoclonal antibodies - the magic bullet.  4:193-199. 1986
  • Management of locally advanced prostatic carcinoma by surgery: does screening for prostatic cancer make sense?.  4:129-135. 1986
  • Treatment of superficial carcinoma of the bladder.  4:52-59. 1986
  • A new technique for the prevention of reflux in those undergoing bladder substitution or undiversion using bowel segments.  3:194-196. 1985
  • Laboratory chemosensitivity testing of human bladder carcinoma.  3:104-109. 1985
  • Prognostic factors predicting treatment response.  2:99-102. 1984
  • Testicular seminoma revisited: Time for a multimodal therapeutic approach.  2:68-72. 1984
  • Editorial comment.  1:2. 1983
  • Radical surgery for the management of prostatic carcinoma.  1:29-35. 1983
  • Single-Centre Experience with the Dual-Focus Storz Modulith SLX-F2 Lithotripter- A Retrospective Study.  3:7-17.